Ligand Pharmaceuticals Incorporated
$ 300.14
-0.80%
06 Aug - close price
- Market Cap 6,015,124,000 USD
- Current Price $ 300.14
- High / Low $ 317.49 / 297.31
- Stock P/E 39.49
- Book Value 49.79
- EPS 7.60
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.17 %
- 52 Week High 326.63
- 52 Week Low 137.14
About
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Analyst Target Price
$343.30
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-14 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 |
| Reported EPS | 2.22 | 1.63 | 2.12 | 3.09 | 0.24 | 1.33 | 1.27 | 1.84 | 1.4 | 1.2 | 1.38 | 1.02 |
| Estimated EPS | 1.34 | 1.8 | 0.63 | 1.93 | 0.21 | 1.21 | 1.1901 | 1.35 | 1.06 | 0.83 | 0.66 | 0.62 |
| Surprise | 0.88 | -0.17 | 1.49 | 1.16 | 0.03 | 0.12 | 0.0799 | 0.49 | 0.34 | 0.37 | 0.72 | 0.4 |
| Surprise Percentage | 65.6716% | -9.4444% | 236.5079% | 60.1036% | 14.2857% | 9.9174% | 6.7137% | 36.2963% | 32.0755% | 44.5783% | 109.0909% | 64.5161% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.08 | $2.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LGND
2026-08-06 21:09:33
Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its expanded commercial portfolio and pipeline catalysts, including several key programs and upcoming trial readouts.
2026-07-30 17:41:29
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that focuses on enabling scientific advancement through financing and licensing its proprietary technologies, such as Captisol and NITRICIL, to support the clinical development of medicines. The company has a market capitalization of $6.26 billion and a P/E TTM of 40.72. Its Contract Revenue-Other business was the largest revenue source in Q1 2026, generating $66.87 million.
2026-07-22 11:11:12
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer, management style, focus (e.g., small cap, health care), expense ratio, assets under management (AUM), current price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds with exposure to Ligand Pharmaceuticals and assess their characteristics.
2026-06-28 12:11:40
Monteverde & Associates PC, an M&A class action firm, is investigating several mergers impacting shareholders of Taylor Morrison Home Corp. (TMHC), Caesars Entertainment, Inc. (CZR), XOMA Royalty Corporation (XOMA), and LiveRamp Holdings, Inc. (RAMP). The firm is encouraging shareholders of these companies to seek information regarding the proposed sale terms and their rights. They emphasize their track record of recovering funds for shareholders through litigation.
2026-06-25 20:41:20
Ligand Pharmaceuticals has successfully completed a $700 million private offering of 0.00% Convertible Senior Notes due 2031 to enhance its liquidity and financial flexibility. To mitigate dilution, the company entered into convertible note hedge transactions covering approximately 2.09 million shares and sold warrants with a $524.34 strike price, covering about 4.19 million shares, to help offset hedging costs. The notes are initially convertible at $334.27 per share and are senior unsecured.
2026-06-22 23:11:45
Ligand Pharmaceuticals announced a private offering of $550 million in convertible senior notes due 2031, with an option for an additional $82.5 million. The company plans to use part of the proceeds for convertible note hedge and warrant transactions, repurchase up to $75 million of its common stock, and fund general corporate purposes, including the acquisition of Xoma Royalty Corporation. Concurrently, a Fourth Amendment to its Credit Agreement was made, adjusting minimum Consolidated EBITDA requirements to facilitate this offering.
